The post SOL Price Prediction: Oversold Bounce Targets $95 by Late February appeared on BitcoinEthereumNews.com. James Ding Feb 10, 2026 06:00 SOL Price PredictionThe post SOL Price Prediction: Oversold Bounce Targets $95 by Late February appeared on BitcoinEthereumNews.com. James Ding Feb 10, 2026 06:00 SOL Price Prediction

SOL Price Prediction: Oversold Bounce Targets $95 by Late February



James Ding
Feb 10, 2026 06:00

SOL Price Prediction Summary • Short-term target (1 week): $91-95 • Medium-term forecast (1 month): $80-110 range • Bullish breakout level: $106 (SMA 20) • Critical support: $80.00 What Crypt…

SOL Price Prediction Summary

• Short-term target (1 week): $91-95
• Medium-term forecast (1 month): $80-110 range
• Bullish breakout level: $106 (SMA 20)
• Critical support: $80.00

What Crypto Analysts Are Saying About Solana

While specific analyst predictions from key opinion leaders are limited, recent forecasts from crypto analysts provide some insight into Solana’s potential trajectory. Rebeca Moen noted on January 9, 2026, that “Solana trades at $138.95 with analysts forecasting $150 targets. Technical analysis reveals key resistance at $142 could unlock 8% upside potential within weeks.” However, SOL has since declined significantly to current levels around $85.

According to on-chain data platforms, Solana’s current positioning suggests the market may be oversold in the near term. The dramatic decline from previous analyst targets indicates either a broader market correction or fundamental shifts in Solana’s valuation metrics.

SOL Technical Analysis Breakdown

Solana’s technical picture presents a mixed but potentially bottoming scenario. The RSI at 28.99 indicates severely oversold conditions, typically suggesting an impending bounce or at least consolidation. This oversold reading often precedes short-term relief rallies, particularly when combined with other technical factors.

The MACD histogram sits at 0.0000, showing bearish momentum has potentially exhausted itself, though no bullish crossover has occurred yet. The Bollinger Band position at 0.20 confirms SOL is trading much closer to the lower band ($72.13) than the upper band ($140.69), reinforcing the oversold narrative.

Key resistance levels emerge at $88.81 (immediate) and $91.66 (strong resistance). The current trading range of $82.86-$88.69 over the past 24 hours suggests consolidation around these critical levels.

Moving averages paint a bearish longer-term picture with SOL trading below all major SMAs. The 7-day SMA at $86.46 sits just above current prices, while the 20-day SMA at $106.41 represents significant overhead resistance.

Solana Price Targets: Bull vs Bear Case

Bullish Scenario

The most immediate bullish target for this SOL price prediction centers on the $91-95 range. Breaking above the strong resistance at $91.66 could trigger momentum toward the 7-day SMA at $86.46, followed by a test of $95-100 levels.

A sustained move above $106.41 (20-day SMA) would signal a genuine trend reversal and open the door to the $120-130 range. This Solana forecast would require significant volume and likely broader crypto market recovery.

The ultimate bullish scenario involves reclaiming the 50-day SMA at $122.42, which could project SOL toward previous analyst targets in the $140-150 range, though this appears unlikely in the near term given current momentum.

Bearish Scenario

The bearish case for SOL centers on a breakdown below the critical $80.00 support level. This could trigger additional selling pressure toward the Bollinger Band lower boundary at $72.13.

A worst-case scenario involves SOL testing the $65-70 range, particularly if broader crypto markets experience additional selling pressure. The significant gap between current prices and all major moving averages suggests the downtrend could persist longer than bulls anticipate.

Risk factors include continued institutional selling, regulatory concerns affecting the Solana ecosystem, or broader market capitulation that could push SOL toward previous cycle lows.

Should You Buy SOL? Entry Strategy

For this SOL price prediction, the current oversold conditions suggest a tactical buying opportunity for risk-tolerant traders. The optimal entry strategy involves scaling into positions between $82-86, with the strongest support at $80.00 serving as a key reference point.

Conservative investors should wait for confirmation above $91.66 before establishing positions, as this would signal the oversold bounce has genuine momentum. More aggressive traders might consider the current $85-86 range attractive given the extreme RSI reading.

Stop-loss placement below $80.00 provides clear risk management, limiting downside to approximately 7-8% from current levels. Position sizing should account for SOL’s high volatility, with the daily ATR of $9.67 indicating significant daily price swings.

Conclusion

This Solana forecast suggests SOL is technically oversold and positioned for a potential bounce toward $91-95 levels over the next 1-2 weeks. However, the broader trend remains bearish with significant overhead resistance at multiple levels.

The SOL price prediction carries moderate confidence given the clear oversold readings, though broader market conditions and momentum indicators suggest any rally may be limited in scope. Traders should approach with appropriate risk management and realistic expectations about the magnitude of any potential recovery.

Disclaimer: Cryptocurrency price predictions are speculative and subject to high volatility. This analysis is for informational purposes only and should not be considered financial advice. Always conduct your own research and consider your risk tolerance before making investment decisions.

Image source: Shutterstock

Source: https://blockchain.news/news/20260210-price-prediction-sol-oversold-bounce-targets-95-by-late

Market Opportunity
Solana Logo
Solana Price(SOL)
$84.3
$84.3$84.3
-1.16%
USD
Solana (SOL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26